Study of Diclofenac Capsules to Treat Osteoarthritis Pain
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Diclofenac
Diclofenac
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Primary diagnosis of Functional Class I-III OA of the hip or knee with documented osteoarthritis flare at baseline
- Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain
- Discontinued all analgesic therapy at Screening
- For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
Exclusion Criteria:
- History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDS, including diclofenac
- Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip
- Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease
- Significant difficulties swallowing capsules or unable to tolerate oral medication
- Previous participation in another clinical study of Diclofenac Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening.
Sites / Locations
- Premier Research Group - Phoenix
- Lynn Institute of the Ozarks
- Acri-Phase I, LLC
- Med Center
- Expresscare Clinical Research
- Westside Center for Clinical Research
- Jacksonville Center for Clinical Research
- Well Pharma Medical Research, Corporation
- Peninsula Research, Inc
- Alliance Clinical Research
- Pinnacle Trials, Inc
- Drug Studies America
- Clinical Investigation Specialists, Inc
- Heartland Research Associates, LLC
- Clinical Trials Technology Inc
- Professional Research Network of Kansas, LLC
- Community Research
- Quest Research Institute
- Healthcare Research
- Sundance Clinical Research, LLC
- Heartland Clinical Research, Inc
- Meridian Clinical Research
- Office of Matthew Barton, MD
- Drug Trials America
- Clinical Study Center of Asheville, LLC
- Triad Clinical Research
- Peters Medical Research
- Sterling Research Group, Ltd
- Community Research
- Community Research
- Sterling Research Group, Ltd
- Radiant Research, Inc
- Altoona Center for Clinical Research
- Radiant Research, Inc
- Premier Research Group - Austin
- Clinical Investigations of Texas, LLC
- Quality Research Inc
- Progressive Clinical Research
- Charlottesville Medical Research Center, LLC
- Hypothetest, LLC
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Diclofenac Capsules 35 mg bid
Diclofenac Capsules 35 mg tid
Placebo Capsule
Arm Description
Outcomes
Primary Outcome Measures
Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference is calculated as the WOMAC pain subscale score assessed at Week 12 minus the WOMAC pain subscale score assessed at baseline.
Secondary Outcome Measures
Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 2 minus the WOMAC pain subscale score assessed at baseline.
Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 6 minus the WOMAC pain subscale score assessed at baseline.
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Weeks 2, 6, and 12 minus the average of the WOMAC pain subscale score assessed at baseline.
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total (Composite) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.
Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total (composite) WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty".
The total (composite) WOMAC score difference was calculated as the total (composite) WOMAC score assessed at Weeks 2, 6, and 12 minus the total (composite) WOMAC score assessed at baseline.
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale.
The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Pain Imaginable".
The VAS pain intensity difference is calculated as the average of the VAS pain intensity scores at Weeks 2, 6, and 12 minus the VAS pain intensity at baseline.
Full Information
NCT ID
NCT01461369
First Posted
October 26, 2011
Last Updated
April 29, 2014
Sponsor
Iroko Pharmaceuticals, LLC
1. Study Identification
Unique Protocol Identification Number
NCT01461369
Brief Title
Study of Diclofenac Capsules to Treat Osteoarthritis Pain
Official Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy and Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
October 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Iroko Pharmaceuticals, LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether Diclofenac [Test] Capsules are safe and effective for the treatment of osteoarthritis pain of the hip or knee.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
305 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diclofenac Capsules 35 mg bid
Arm Type
Experimental
Arm Title
Diclofenac Capsules 35 mg tid
Arm Type
Experimental
Arm Title
Placebo Capsule
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Intervention Description
35 mg bid Capsules
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Intervention Description
35 mg tid Capsules
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Capsules
Primary Outcome Measure Information:
Title
Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
Description
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference is calculated as the WOMAC pain subscale score assessed at Week 12 minus the WOMAC pain subscale score assessed at baseline.
Time Frame
Baseline to Week 12/Early Termination
Secondary Outcome Measure Information:
Title
Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
Description
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 2 minus the WOMAC pain subscale score assessed at baseline.
Time Frame
Baseline to Week 2
Title
Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
Description
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 6 minus the WOMAC pain subscale score assessed at baseline.
Time Frame
Baseline to Week 6
Title
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
Description
The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain".
The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Weeks 2, 6, and 12 minus the average of the WOMAC pain subscale score assessed at baseline.
Time Frame
Baseline to Week 12/Early Termination
Title
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total (Composite) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.
Description
Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total (composite) WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty".
The total (composite) WOMAC score difference was calculated as the total (composite) WOMAC score assessed at Weeks 2, 6, and 12 minus the total (composite) WOMAC score assessed at baseline.
Time Frame
Baseline to Week 12/Early Termination
Title
Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale.
Description
The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Pain Imaginable".
The VAS pain intensity difference is calculated as the average of the VAS pain intensity scores at Weeks 2, 6, and 12 minus the VAS pain intensity at baseline.
Time Frame
Baseline to Week 12/Early Termination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Primary diagnosis of Functional Class I-III OA of the hip or knee with documented osteoarthritis flare at baseline
Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain
Discontinued all analgesic therapy at Screening
For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
Exclusion Criteria:
History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDS, including diclofenac
Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip
Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease
Significant difficulties swallowing capsules or unable to tolerate oral medication
Previous participation in another clinical study of Diclofenac Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John M Agaiby, MD
Organizational Affiliation
Clinical Investigation Specialists, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eddie Armas, MD
Organizational Affiliation
Well Pharma Medical Research, Corporation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Matthew Barton, MD
Organizational Affiliation
Office of Matthew Barton, MD
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Bouda, MD
Organizational Affiliation
Heartland Clinical Research, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Venkata Challa, MD
Organizational Affiliation
Peters Medical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Champlin, MD
Organizational Affiliation
Med Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Francisco Chevres, MD
Organizational Affiliation
Pinnacle Trials, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Melanie Christina, MD
Organizational Affiliation
Clinical Investigations of Texas, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
James R Clark, MD
Organizational Affiliation
Charlottesville Medical Research Center, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stephen Daniels, DO
Organizational Affiliation
Premier Research Group - Austin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard R Eckert, MD
Organizational Affiliation
Hypothetest, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brandon Essink, MD
Organizational Affiliation
Meridian Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard M Glover, MD
Organizational Affiliation
Heartland Research Associates, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kent S Hoffman, DO
Organizational Affiliation
Alliance Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Curtis S Horn, MD
Organizational Affiliation
Quality Research Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Raymond E Jackson, MD
Organizational Affiliation
Quest Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeffry Jacqmein, MD
Organizational Affiliation
Jacksonville Center For Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Enrico Jones, MD
Organizational Affiliation
Triad Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alan Kivitz, MD
Organizational Affiliation
Altoona Center for Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kevin Kuettel, MD
Organizational Affiliation
ACRI-Phase I, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gregory F Lakin, DO
Organizational Affiliation
Professional Research Network of Kansas, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Theresia Lee, MD
Organizational Affiliation
Progressive Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sathish Modugu, MD
Organizational Affiliation
Drug Trials America
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julie A Mullen, DO
Organizational Affiliation
Sterling Research Group, Ltd
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kashyap Patel, MD
Organizational Affiliation
Peninsula Research, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kyle Patrick, DO
Organizational Affiliation
Premier Research Group - Phoenix
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Antoinette A Pragalos, MD
Organizational Affiliation
Community Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Larry D Reed, MD, PhD
Organizational Affiliation
Healthcare Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eli M Roth, MD
Organizational Affiliation
Sterling Research Group, Ltd
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Douglas R Schumacher, MD
Organizational Affiliation
Radiant Research, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mark Stich, DO
Organizational Affiliation
Westside Center for Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bradley Swenson, MD
Organizational Affiliation
Radiant Research, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marvin Tark, MD
Organizational Affiliation
Drug Studies America
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gary Tarshis, MD
Organizational Affiliation
Expresscare Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Haydn M Thomas, MD
Organizational Affiliation
Clinical Trials Technology Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cindy Tuten, MD
Organizational Affiliation
Clinical Study Center of Asheville, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Larkin T Wadsworth, MD
Organizational Affiliation
Sundance Clinical Research, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert J Wagner, MD
Organizational Affiliation
Community Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Larry S Watkins, MD
Organizational Affiliation
Lynn Institute of the Ozarks
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tamela Zimmerman, MD
Organizational Affiliation
Community Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Premier Research Group - Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85027
Country
United States
Facility Name
Lynn Institute of the Ozarks
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Acri-Phase I, LLC
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Med Center
City
Carmichael
State/Province
California
ZIP/Postal Code
95608
Country
United States
Facility Name
Expresscare Clinical Research
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80909
Country
United States
Facility Name
Westside Center for Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32205
Country
United States
Facility Name
Jacksonville Center for Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Well Pharma Medical Research, Corporation
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Peninsula Research, Inc
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Alliance Clinical Research
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32792
Country
United States
Facility Name
Pinnacle Trials, Inc
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Facility Name
Drug Studies America
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Clinical Investigation Specialists, Inc
City
Gurnee
State/Province
Illinois
ZIP/Postal Code
60031
Country
United States
Facility Name
Heartland Research Associates, LLC
City
Newton
State/Province
Kansas
ZIP/Postal Code
67114
Country
United States
Facility Name
Clinical Trials Technology Inc
City
Prairie Village
State/Province
Kansas
ZIP/Postal Code
66206
Country
United States
Facility Name
Professional Research Network of Kansas, LLC
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67203
Country
United States
Facility Name
Community Research
City
Crestview Hills
State/Province
Kentucky
ZIP/Postal Code
41017
Country
United States
Facility Name
Quest Research Institute
City
Bingham Farms
State/Province
Michigan
ZIP/Postal Code
48025
Country
United States
Facility Name
Healthcare Research
City
Florissant
State/Province
Missouri
ZIP/Postal Code
63031
Country
United States
Facility Name
Sundance Clinical Research, LLC
City
St Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Heartland Clinical Research, Inc
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68134
Country
United States
Facility Name
Meridian Clinical Research
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68134
Country
United States
Facility Name
Office of Matthew Barton, MD
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Drug Trials America
City
Hartsdale
State/Province
New York
ZIP/Postal Code
10530
Country
United States
Facility Name
Clinical Study Center of Asheville, LLC
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28803
Country
United States
Facility Name
Triad Clinical Research
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Peters Medical Research
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
Sterling Research Group, Ltd
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Community Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States
Facility Name
Community Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45245
Country
United States
Facility Name
Sterling Research Group, Ltd
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
Radiant Research, Inc
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43212
Country
United States
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Radiant Research, Inc
City
Anderson
State/Province
South Carolina
ZIP/Postal Code
29621
Country
United States
Facility Name
Premier Research Group - Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Clinical Investigations of Texas, LLC
City
Plano
State/Province
Texas
ZIP/Postal Code
75075
Country
United States
Facility Name
Quality Research Inc
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
Progressive Clinical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Charlottesville Medical Research Center, LLC
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22911
Country
United States
Facility Name
Hypothetest, LLC
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24018
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
25050589
Citation
Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Curr Med Res Opin. 2014 Sep;30(9):1883-93. doi: 10.1185/03007995.2014.946123. Epub 2014 Aug 6.
Results Reference
derived
Learn more about this trial
Study of Diclofenac Capsules to Treat Osteoarthritis Pain
We'll reach out to this number within 24 hrs